Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions

By D. Gladstone, Sandra E. Black, A. Hakim. Stroke, 2002

680 citations recorded by the source corpus.

Subfields: Epidemiology, Neurology

View Paper: https://www.semanticscholar.org/paper/aaa877c19a347ebfc81fd6a95eb13d3977621ec2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. S. Carmichael
2. Myron D. Ginsberg
3. A. Broeck
4. S. Cruchten

In Neurology

1. S. Carmichael
2. W. Dietrich
3. Helen M. Bramlett
4. Myron D. Ginsberg

Citations in the corpus

• A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia (2003, background): “Although several neuroprotective strategies were able to reduce the lesion volume in animal models, clinical trials have not been successful up to no”
• Pathophysiology of Cerebral Ischemia and Brain Trauma: Similarities and Differences (2004, background): “Despite the identification of these processes and the development of novel pharmacological agents, clinical trials in stroke and TBI have met with little success (Doppenberg and Bullock, 1997; Gladstone et al., 2002).”
• 1,026 Experimental treatments in acute stroke (2006, background): “For these and other reasons, animal studies tend to place a heavy reliance upon infarct volume compared with functional outcome measures more commonly used in the clinical context.(2) Nevertheless, it is recommended that preclinical studies use both functional and histological outcomes.”
• Rodent models of focal stroke: Size, mechanism, and purpose (2005, background): “oxidative injury, the main targets for neuroprotective therapies.(3,4)”
• Interleukin-1 and neuronal injury (2005, background): “This is probably a consequence of multiple factors, including the limitations of preclinical data, the difficulty in optimizing clinical design and the diversity of the conditio”
• NMDA Receptor Subunits Have Differential Roles in Mediating Excitotoxic Neuronal Death Both In Vitro and In Vivo (2007, background): “neuroprotection resulting from side effects, the inability to administer the drugs within their neuroprotective windows, poor experimental designs, and heterogeneity in the patient population (Corbett and Nurse, 1998; Gladstone et al., 2002; Ikonomidou and Turski, 2002; Albensi et al., 2004).”